Snoring is a massive problem affecting 100M+ people in the US alone. On a global scale, there are almost 600 million snorers in developed countries. We solve the snoring problem with our patented mouthguards which boasts a 91% success rate proven via an FDA-approved clinical study.
Capturing just 10% of the US market is worth $1B in revenue. Capturing just 0.2% of the snorers in developed countries worldwide is worth $1.2B in revenue. Join the market leaders in stopping snoring as we scale and become the go-to brand for all things sleep.
DAYS
HOURS
MINUTES
In sales to date
Customers
Products sold
Paid for inventory on hand
FDA Cleared
Receive:
Free Zyppah Anti-Snoring Mouthpiece
Receive:
5% bonus shares
Free Zyppah Anti-Snoring Mouthpiece
Receive
7.5% bonus shares
Presidents Circle (Max 100 Members)
Plaque/Certificate
Quarterly Update Meeting with Founder & CEO
As new products come to market, you will get a free sample.
Participation in new product testing and launches (Member of ZYPPAH's new product evaluation committee)
Receive
7.5% bonus shares
Presidents Circle
VIP Trip to LA
Air travel for two
2 Nights Premier Hotel
Day Spent with the president + CEO
Snoring isn’t just annoying, it’s a major health problem. People who snore get worse sleep, wake up feeling tired, and are at higher risk for a number of health problems.3
Weakened Immune System
Obstructive Sleep Apnea
Sleep Deprivation
Weight Gain
Inability To Lose Weight
Type 2 Diabetes
GERD
Heart Disease
High Blood Pressure
Stroke
Alzheimer's
Cancer
Snoring is caused by the tongue obstructing the airway. We’ve made the only anti-snoring aid that directly stops the tongue from blocking the airway. That’s why we had a 91% success rate in an FDA-approved clinical study (compared to 15% to 45% for our competitors).4
Clinically tested and patented band stabilizes the tongue
Self molded for a custom fit and unsurpassed comfort
Mandibular advancement moves the jaw forward for improved airflow
Our 400,000+ customers and $55M in revenue to date prove an anti-snoring device that actually works is in high demand. This is an opportunity to invest in a winning company as we prepare to scale.
$55M+ in sales to date
400,000+ customers
1,000s of 5-star reviews
Our biggest opportunities are ahead of us. With over 100 million snorers in the US alone, a 10% penetration of the market generates over $1B in revenue. Capturing just 0.2% of the snorers in developed countries worldwide is worth $1.2B in revenue.
By joining us as an investor, you can share in our growth as we grow into this market and help people who snore get better sleep, wake up refreshed, and reduce the higher risks for a number of health problems.5
As a direct-to-consumer brand, we can keep our costs low and our margins high. We don’t need a large sales team or our own brick-and-mortar stores to scale our brand. Not needing to build an extensive infrastructure is a massive benefit when scaling a company.
We aim to leverage our brand as the market leader in anti-snoring devices to expand into more sleep products, including pillows, sleep aids, and even a snoring app. We plan to increase marketing spend in our domestic market while we also expanding internationally
3-6 months to bring to market
3-6 months to bring to market
3-6 months to bring to market
3-6 months to bring to market
3-6 months to bring to market
6 months after full funding
Chairman
Dr. Greenburg is a leading name in the snoring & sleep apnea industries. He is well known in the dental world and the consumer marketplace. He has treated thousands of patients with snoring & sleep apnea. He also has significant, successful experience working with the FDA.
Dr. Greenburg received one of the first degrees in Biomedical Engineering from Syracuse University. This was immediately followed with a DDS degree from New York University. He founded his successful dental practice in Los Angeles, CA in 1982. He sold the practice in 1991 and entered the corporate arena gaining significant experience with early-stage companies.
In 2001, he returned to the full-time practice of dentistry and began to study snoring & sleep apnea. Frustrated that only 10% of the US population was being treated for this devastating condition, he resolved to solve the problem.
In 2006, he invented a revolutionary new oral/dental appliance for the treatment of snoring & obstructive sleep apnea for which there are a number of patents approved and pending. These appliances are unique because they are the only true “hybrid” appliances, both advancing the jaw and managing the tongue. The FDA cleared his appliances in 2012 for sale in the US.
Read Bio +
Close Bio -
.jpeg)
CEO
Lawrence Biggs has founded and served as CEO of both private and publicly traded technology and service companies. His expertise includes raising capital, mergers and acquisitions, building corporate infrastructure, developing technology-related products, marketing technology products, achieving rapid sales growth, attracting and retaining talented staff, finding and consummating strategic relationships, and communicating to the private and public equity markets.
Mr. Biggs’ expertise is in early-stage companies, launching products, growing companies, raising capital, and taking companies public. His involvement immediately prior to Zyppah Inc. was with Vivos Therapeutics, also in the sleep space, where he served as advisor to the CEO and consulted regarding the Company’s capital raise and IPO, including providing and managing a road show for the Company to various investment banks.
The Company ultimately engaged Roth Capital, introduced by Mr. Biggs, which raised $80 million in an IPO and additional offerings. Mr. Biggs founded and served as CEO of Max Internet Inc., a Company with rapid growth resulting in a public issue on the NASDAQ stock exchange. The Company manufactured and marketed a computer board utilized for video conferencing and video streaming, earning a patent for the product. Under Mr. Biggs’ guidance as CEO, Max Internet reached a peak market capitalization of $1.4 billion on the NASDAQ exchange. (NASDAQ: MXIP)
Mr. Biggs has also served as CEO of additional public companies including MMAX Media (OTCBB: NEPR) a Mixed Marshal Arts television programming Company, and StereoVision (OTCBB: SVSN) a 3D film company. He also founded the private companies of Rawkin Bliss, Cardio Supply, Pre-Check Health and Spectrum Communications, which granted Mr. Biggs the patent for the Access Phone and was installed across the country in 220,000 hotel rooms.
Read Bio +
Close Bio -
$1.00
$500
Common
$1,102,100
$25M
In short, ZYPPAH has a solution to snoring that works twice as well as their nearest competitor, is patented and FDA approved, making it almost impossible to copy or compete against. They’ve proven the market wants this solution with $55M in sales already to 400K customers with less than 7% return rate and thousands of 5 star reviews. They’ve only scratched the surface of their true potential, where capturing just 3% of the American market (100 million people who snore) could generate $100M in sales a year. And more and more people are paying attention to sleep hygiene, making the sleep aid market worth more than $73B.
They’ve already proven they can with $55M in sales. And as a DTC brand, they don’t have the overhead of many other companies. Their mouth guards boast an 85% gross profit margin.
400,000 people have already.
Only 3% of America's snorers have even looked for a solution yet. This leaves open 97% of a massive untapped market for ZYPPAH. Plus they have new products they plan to roll out to leverage their brand and capture more of the sleep market. They aim to be the Apple of sleep.
The brilliance of ZYPPAH lies in its patented design, which effectively addresses the root cause of snoring, the tongue. The unparalleled results are clearly shown in FDA clinical trials that demonstrated a 91% rate of success. Our competitors can't replicate our product without infringing on our patent rights, and therefore can't achieve the same level of success.
We plan to increase marketing spend in our domestic market while we also expanding internationally.
Invest $500
Receive: Free Zyppah Anti-Snoring Mouthpiece
Invest $5,000
Receive: 5% Bonus + Free Zyppah Anti-Snoring Mouthpiece
Invest $10,000
Receive: 7.5% Bonus
Presidents Circle (Max 100 Members)
Plaque/Certificate
Quarterly Update Meeting with Founder & CEO
As new products come to market, you will get a free sample.
Participation in new product testing and launches (Member of ZYPPAH’s new product evaluation committee)
Invest $50,000
7.5% Bonus
Presidents Circle
VIP Trip to LA
Air travel for two
2 Nights Premier Hotel
Day Spent with the president + CEO
We are focused on combating snoring to provide better sleep for our consumers
Shares will be rewarded after the investment funds clear. This typically takes around 3 weeks after investment.
No, costs are the same, regardless of how you invest
No
Regulation CF allows investors to invest in startups and early-growth companies. This is different from helping a company raise money on Kickstarter; with Regulation CF Offerings, you aren’t buying products or merchandise - you are buying a piece of a company and helping it grow.
Accredited investors can invest as much as they want. But if you are NOT an accredited investor, your investment limit depends on either your annual income or net worth, whichever is greater. If the number is less than $124,000, you can only invest 5% of it. If both are greater than $124,000 then your investment limit is 10%.
To calculate your net worth, just add up all of your assets and subtract all of your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
Individuals over 18 years of age can invest.
There will always be some risk involved when investing in a startup or small business. And the earlier you get in the more risk that is usually present. If a young company goes out of business, your ownership interest could lose all value. You may have limited voting power to direct the company due to dilution over time. You may also have to wait about five to seven years (if ever) for an exit via acquisition, IPO, etc. Because early-stage companies are still in the process of perfecting their products, services, and business model, nothing is guaranteed. That’s why startups should only be part of a more balanced, overall investment portfolio.
The Common Stock (the "Shares") of [Zyppah] (the "Company") are not publicly-traded. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically look to receive a return on your investment under the following scenarios: The Company gets acquired by another company. The Company goes public (makes an initial public offering). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on an exchange. These are both considered long-term exits, taking approximately 5-10 years (and often longer) to see the possibility for an exit. It can sometimes take years to build companies. Sometimes there will not be any return, as a result of business failure.
Shares sold via Regulation Crowdfunding offerings have a one-year lockup period before those shares can be sold under certain conditions.
In the event of death, divorce, or similar circumstance, shares can be transferred to:
If a company does not reach their minimum funding target, all funds will be returned to the investors after the close of the offering.
All available disclosure information can be found on the offering pages for our Regulation Crowdfunding offering.
You can cancel your investment at any time, for any reason, until 48 hours prior to a closing occurring. If you’ve already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: investor@zyppah.com
At a minimum, the company will be filing with the SEC and posting on its website an annual report, along with certified financial statements. Those should be available 120 days after the fiscal year end. If the company meets a reporting exception, or eventually has to file more reported information to the SEC, the reporting described above may end. If these reports end, you may not continually have current financial information about the company.
Once an offering ends, the company may continue its relationship with DealMaker Securities for additional offerings in the future. DealMaker Securities’ affiliates may also provide ongoing services to the company. There is no guarantee any services will continue after the offering ends.
